NCT00948389 - Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Glioblastoma

Interventions

DRUG

Dasatinib

Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity

DRUG

Lomustine

Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity

Trial Locations (5)

Local Institution, Lausanne

Local Institution, Bologna

Local Institution, Paris

Local Institution, Nijmegen

Local Institution, Rotterdam